<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392870</url>
  </required_header>
  <id_info>
    <org_study_id>CSPT04_TAVA</org_study_id>
    <nct_id>NCT03392870</nct_id>
  </id_info>
  <brief_title>Evaluation of a Clinical Transitional Program in Autism</brief_title>
  <acronym>TAVA</acronym>
  <official_title>Evaluation of a Clinical Program Specialized in the Diagnosis, Follow-up and Treatment of Young Adults With a Autism Spectrum Disorder: &quot;TAVA&quot; (Spanish Acronym for &quot;Support to Subjects With Autism in Their Transition to Adulthood&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial without drug, randomized: Comparison of a specific and integrative clinical
      protocol for young adults with autism to usual treatment. It will include both low and
      high-functioning participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A researcher will be masked for group aleatorization (active, group) in order to unbiasedly evaluate outcomes which require subjective assesment of functionality.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of life.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The World Health Organization Quality of Life (WHOQOL). Self-administered scale, quantitative. Spanish version.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in: Asperger Symptoms.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Adult Asperger Assessment (AAA). Includes questionnaire (autism spectrum quotient, AQ) and (empathy quotient, EQ). Self-administered scale, quantitative.Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Depressive symptoms</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Beck Depression Inventory-II (BDI-II) . Self-administered scale, quantitative.Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Anxiety Symptoms.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Beck Anxiety Inventory (BAI). Self-administered scale, quantitative.Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Obsessive-compulsive symptoms.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Obsessive-Compulsive Inventory - Revised (OCI-R). Self-administered scale, quantitative. Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: ASD symptoms evaluated by parents/caregiver.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Social Responsiveness Scale (SRS). Parents' self-administered scale, quantitative.Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: ASD symptoms.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Ritvo Autism Asperger's Diagnostic Scale (RAADS-R). Self-administered scale, quantitative. Spanish- translated version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Social phobia symptoms.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Social Phobia Inventory (SPIN). Self-administered scale, quantitative. Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Evaluation of support needs.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Camberwell Assessment of Need, revised (CAN-R). Administered by the professional, qualitative. Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Caregiver's burden associated with the disorder.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The Zarit Burden Interview. Caregiver self-report, quantitative. Spanish version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in: Evaluation of the level of autonomy, self-regulation, self-empowerment, self-knowledge.</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The Arc's Self-Determination Scale. Self-administered scale. Spanish version. Quantitative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>TAVA-ACTIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient&gt;70, verbal communication and no behavioural alterations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Integrative interventional programme</intervention_name>
    <description>The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.</description>
    <arm_group_label>TAVA-ACTIVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>As usual</intervention_name>
    <description>The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASD diagnosis

          -  Previous follow-up by child and adolescent psychiatry department at Corporació
             Sanitària Parc Taulí (CSPT)

        Exclusion Criteria:

        - Living in a disabled residential setting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ESTHER VIA, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CORPORACIO SANITARIA PARC TAULI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ESTHER VIA, PHD</last_name>
    <phone>0034937240182</phone>
    <email>evia@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Parra, MD</last_name>
    <phone>937 23 10 10</phone>
    <phone_ext>21761</phone_ext>
    <email>iparra@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ESTHER VIA, PHD</last_name>
      <phone>0034937240182</phone>
      <email>evia.tauli@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Esther Via</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorder (ASD)</keyword>
  <keyword>Transition program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

